BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Preuß EB, Schubert S, Werlein C, Stark H, Braubach P, Höfer A, Plucinski EKJ, Shah HR, Geffers R, Sewald K, Braun A, Jonigk DD, Kühnel MP. The challenge of long-term cultivation of human precision-cut lung slices. Am J Pathol 2021:S0002-9440(21)00481-8. [PMID: 34767811 DOI: 10.1016/j.ajpath.2021.10.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Steinestel K, Tischler V. [Update thoracic pathology 2022-Report of the Thoracic Pathology Working Group of the German Society of Pathology]. Pathologie (Heidelb) 2022. [PMID: 36260123 DOI: 10.1007/s00292-022-01141-w] [Reference Citation Analysis]
2 Nußbaum SM, Krabbe J, Böll S, Babendreyer A, Martin C. Functional changes in long-term incubated rat precision-cut lung slices. Respir Res 2022;23:261. [PMID: 36127699 DOI: 10.1186/s12931-022-02169-5] [Reference Citation Analysis]
3 Meineke R, Stelz S, Busch M, Werlein C, Kühnel M, Jonigk D, Rimmelzwaan GF, Elbahesh H. FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections. Viruses 2022;14:2058. [PMID: 36146864 DOI: 10.3390/v14092058] [Reference Citation Analysis]
4 Meineke R, Stelz S, Busch M, Werlein C, Kühnel M, Jonigk D, Rimmelzwaan GF, Elbahesh H. Ex Vivo Validation of Six FDA-Approved Non-Receptor Tyrosine Kinase Inhibitors (NRTKIs) as Antivirals to Pandemic and Seasonal Influenza A Viruses.. [DOI: 10.1101/2022.01.19.476993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]